Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

OPEN ACCESS
SEARCH
Search

Previous issues

Page Path
HOME > BROWSE ARTICLES > Previous issues
25 Previous issues
Filter
Filter
Article type
Keywords
Authors
Funded articles
Volume 36(3); June 2021
Prev issue Next issue
Review Articles
Diabetes, Obesity and Metabolism
Recent Advances in Understanding Peripheral Taste Decoding I: 2010 to 2020
Jea Hwa Jang, Obin Kwon, Seok Jun Moon, Yong Taek Jeong
Endocrinol Metab. 2021;36(3):469-477.   Published online June 18, 2021
DOI: https://doi.org/10.3803/EnM.2021.302
  • 9,647 View
  • 299 Download
  • 3 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Taste sensation is the gatekeeper for direct decisions on feeding behavior and evaluating the quality of food. Nutritious and beneficial substances such as sugars and amino acids are represented by sweet and umami tastes, respectively, whereas noxious substances and toxins by bitter or sour tastes. Essential electrolytes including Na+ and other ions are recognized by the salty taste. Gustatory information is initially generated by taste buds in the oral cavity, projected into the central nervous system, and finally processed to provide input signals for food recognition, regulation of metabolism and physiology, and higher-order brain functions such as learning and memory, emotion, and reward. Therefore, understanding the peripheral taste system is fundamental for the development of technologies to regulate the endocrine system and improve whole-body metabolism. In this review article, we introduce previous widely-accepted views on the physiology and genetics of peripheral taste cells and primary gustatory neurons, and discuss key findings from the past decade that have raised novel questions or solved previously raised questions.

Citations

Citations to this article as recorded by  
  • Physiology of the tongue with emphasis on taste transduction
    Máire E. Doyle, Hasitha U. Premathilake, Qin Yao, Caio H. Mazucanti, Josephine M. Egan
    Physiological Reviews.2023; 103(2): 1193.     CrossRef
  • Polycystic kidney disease 2-like 1 channel contributes to the bitter aftertaste perception of quinine
    Takahiro Shimizu, Takuto Fujii, Keisuke Hanita, Ryo Shinozaki, Yusaku Takamura, Yoshiro Suzuki, Teppei Kageyama, Mizuki Kato, Hisao Nishijo, Makoto Tominaga, Hideki Sakai
    Scientific Reports.2023;[Epub]     CrossRef
  • Sweet Taste Preference: Relationships with Other Tastes, Liking for Sugary Foods and Exploratory Genome-Wide Association Analysis in Subjects with Metabolic Syndrome
    Rebeca Fernández-Carrión, Jose V. Sorlí, Oscar Coltell, Eva C. Pascual, Carolina Ortega-Azorín, Rocío Barragán, Ignacio M. Giménez-Alba, Andrea Alvarez-Sala, Montserrat Fitó, Jose M. Ordovas, Dolores Corella
    Biomedicines.2021; 10(1): 79.     CrossRef
Diabetes, Obesity and Metabolism
Receptor-Mediated Muscle Homeostasis as a Target for Sarcopenia Therapeutics
Jong Hyeon Yoon, Ki-Sun Kwon
Endocrinol Metab. 2021;36(3):478-490.   Published online June 28, 2021
DOI: https://doi.org/10.3803/EnM.2021.1081
  • 6,969 View
  • 271 Download
  • 5 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Sarcopenia is a disease characterized by age-related decline of skeletal muscle mass and function. The molecular mechanisms of the pathophysiology of sarcopenia form a complex network due to the involvement of multiple interconnected signaling pathways. Therefore, signaling receptors are major targets in pharmacological strategies in general. To provide a rationale for pharmacological interventions for sarcopenia, we herein describe several druggable signaling receptors based on their role in skeletal muscle homeostasis and changes in their activity with aging. A brief overview is presented of the efficacy of corresponding drug candidates under clinical trials. Strategies targeting the androgen receptor, vitamin D receptor, Insulin-like growth factor-1 receptor, and ghrelin receptor primarily focus on promoting anabolic action using natural ligands or mimetics. Strategies involving activin receptors and angiotensin receptors focus on inhibiting catabolic action. This review may help to select specific targets or combinations of targets in the future.

Citations

Citations to this article as recorded by  
  • Impact of Vitamin D Level on Sarcopenia in Elderly People: A Critical Review
    Saniya Khan, Sunil Kumar, Sourya Acharya, Anil Wanjari
    Journal of Health and Allied Sciences NU.2023;[Epub]     CrossRef
  • Alverine citrate promotes myogenic differentiation and ameliorates muscle atrophy
    Jong Hyeon Yoon, Seung-Min Lee, Younglang Lee, Min Ju Kim, Jae Won Yang, Jeong Yi Choi, Ju Yeon Kwak, Kwang-Pyo Lee, Yong Ryoul Yang, Ki-Sun Kwon
    Biochemical and Biophysical Research Communications.2022; 586: 157.     CrossRef
  • Adeno-associated virus-mediated expression of an inactive CaMKIIβ mutant enhances muscle mass and strength in mice
    Takahiro Eguchi, Yuji Yamanashi
    Biochemical and Biophysical Research Communications.2022; 589: 192.     CrossRef
  • Gastric Mobility and Gastrointestinal Hormones in Older Patients with Sarcopenia
    Hsien-Hao Huang, Tse-Yao Wang, Shan-Fan Yao, Pei-Ying Lin, Julia Chia-Yu Chang, Li-Ning Peng, Liang-Kung Chen, David Hung-Tsang Yen
    Nutrients.2022; 14(9): 1897.     CrossRef
  • Molecular Mechanisms Underlying Intensive Care Unit-Acquired Weakness and Sarcopenia
    Marcela Kanova, Pavel Kohout
    International Journal of Molecular Sciences.2022; 23(15): 8396.     CrossRef
Thyroid
Antithyroid Drug Treatment in Graves’ Disease
Jae Hoon Chung
Endocrinol Metab. 2021;36(3):491-499.   Published online June 16, 2021
DOI: https://doi.org/10.3803/EnM.2021.1070
  • 3,261 View
  • 259 Download
  • 6 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Graves’ disease is associated with thyrotropin (TSH) receptor stimulating antibody, for which there is no therapeutic agent. This disease is currently treated through inhibition of thyroid hormone synthesis or destruction of the thyroid gland. Recurrence after antithyroid drug (ATD) treatment is common. Recent studies have shown that the longer is the duration of use of ATD, the higher is the remission rate. Considering the relationship between clinical outcomes and iodine intake, recurrence of Graves’ disease is more common in iodine-deficient areas than in iodine-sufficient areas. Iodine restriction in an iodine-excessive area does not improve the effectiveness of ATD or increase remission rates. Recently, Danish and Korean nationwide studies noted significantly higher prevalence of birth defects in newborns exposed to ATD during the first trimester compared to that of those who did not have such exposure. The prevalence of birth defects was lowest when propylthiouracil (PTU) was used and decreased by only 0.15% when methimazole was changed to PTU in the first trimester. Therefore, it is best not to use ATD in the first trimester or to change to PTU before pregnancy.

Citations

Citations to this article as recorded by  
  • Выраженность окислительного стресса и энзиматическая активность нейтрофилов крови у пациентов с болезнью Грейвса в зависимости от компенсации гипертиреоза
    М. А. Дудина, С. А. Догадин, А. А. Савченко, И. И. Гвоздев
    Ateroscleroz.2023; 18(4): 411.     CrossRef
  • Application of oral inorganic iodine in the treatment of Graves’ disease
    Yixuan Huang, Yihang Xu, Murong Xu, Xiaotong Zhao, Mingwei Chen
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Sex-specific risk factors associated with graves’ orbitopathy in Korean patients with newly diagnosed graves’ disease
    Jooyoung Lee, Jinmo Kang, Hwa Young Ahn, Jeong Kyu Lee
    Eye.2023;[Epub]     CrossRef
  • Usefulness of Real-Time Quantitative Microvascular Ultrasonography for Differentiation of Graves’ Disease from Destructive Thyroiditis in Thyrotoxic Patients
    Han-Sang Baek, Ji-Yeon Park, Chai-Ho Jeong, Jeonghoon Ha, Moo Il Kang, Dong-Jun Lim
    Endocrinology and Metabolism.2022; 37(2): 323.     CrossRef
  • The chemiluminescent and enzymatic activity of blood neutrophils in patients with Graves' disease depending on hyperthyroidism compensation
    M. A. Dudina, A. A. Savchenko, S. A. Dogadin, I. I. Gvozdev
    Clinical and experimental thyroidology.2022; 18(1): 4.     CrossRef
  • Risk of Diabetes in Patients with Long-Standing Graves’ Disease: A Longitudinal Study
    Eyun Song, Min Ji Koo, Eunjin Noh, Soon Young Hwang, Min Jeong Park, Jung A Kim, Eun Roh, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo
    Endocrinology and Metabolism.2021; 36(6): 1277.     CrossRef
Thyroid
Subclinical Hypothyroidism: Prevalence, Health Impact, and Treatment Landscape
Won Sang Yoo, Hyun Kyung Chung
Endocrinol Metab. 2021;36(3):500-513.   Published online June 18, 2021
DOI: https://doi.org/10.3803/EnM.2021.1066
  • 4,914 View
  • 342 Download
  • 9 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Subclinical hypothyroidism (sHypo) is defined as normal serum free thyroid hormone levels coexisting with elevated serum thyroid-stimulating hormone (TSH) levels. sHypo is a common condition observed in clinical practice with several unique features. Its diagnosis should be based on an understanding of geographic and demographic differences in biochemical criteria versus a global reference range for TSH that is based on the 95% confidence interval of a healthy population. During the differential diagnosis, it is important to remember that a considerable proportion of sHypo cases are transient and reversible in nature; the focus is better placed on persistent or progressive forms, which mainly result from chronic autoimmune thyroiditis. Despite significant evidence documenting the health impacts of sHypo, the effects of levothyroxine treatment (LT4-Tx) in patients with sHypo remains controversial, especially in patients with grade 1 sHypo and older adults. Existing evidence suggests that it is reasonable to refrain from immediate LT4-Tx in most patients if they are closely monitored, except in women who are pregnant or in progressive cases. Future research is needed to further characterize the risks and benefits of LT4-Tx in different patient cohorts.

Citations

Citations to this article as recorded by  
  • Subclinical hypothyroidism, outcomes and management guidelines: a narrative review and update of recent literature
    Bogumila Urgatz, Salman Razvi
    Current Medical Research and Opinion.2023; 39(3): 351.     CrossRef
  • Indicator of thyroid hormones in newborns from mothers with diffuse-endemic goiter
    G. T. Makhkamova, Sh. T. Turdieva
    Meditsinskiy sovet = Medical Council.2023; (1): 212.     CrossRef
  • Diagnóstico y tratamiento del hipotiroidismo subclínico en adultos mayores
    Debbie Noelia Tebanta Albán, Gabriel Aníbal Hugo Merino, María Valentina Muñoz Arteaga, Ariana Lisseth Vázquez López
    Ciencia Digital.2023; 7(1): 6.     CrossRef
  • Comparison of Five Different Criteria for Diagnosis of Subclinical Hypothyroidism in a Large-Scale Chinese Population
    Yan-song Zheng, Sheng-yong Dong, Yan Gong, Jia-hong Wang, Fei Wang, Qiang Zeng
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Subclinical Hypothyroidism and Cognitive Impairment
    Jung-Min Pyun, Young Ho Park, SangYun Kim
    Journal of Alzheimer's Disease.2022; 88(2): 757.     CrossRef
  • Effect of Levothyroxine Supplementation on the Cardiac Morphology and Function in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis
    Xichang Wang, Haoyu Wang, Qiuxian Li, Ping Wang, Yumin Xing, Fan Zhang, Jiashu Li, Zhongyan Shan
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(9): 2674.     CrossRef
  • Natural history of subclinical hypothyroidism and prognostic factors for the development of overt hypothyroidism: Tehran Thyroid Study (TTS)
    A. Amouzegar, M. Dehghani, H. Abdi, L. Mehran, S. Masoumi, F. Azizi
    Journal of Endocrinological Investigation.2022; 45(12): 2353.     CrossRef
  • Retrospective cohort analysis comparing changes in blood glucose level and body composition according to changes in thyroid‐stimulating hormone level
    Hyunah Kim, Da Young Jung, Seung‐Hwan Lee, Jae‐Hyoung Cho, Hyeon Woo Yim, Hun‐Sung Kim
    Journal of Diabetes.2022; 14(9): 620.     CrossRef
  • Long working hours and risk of hypothyroidism in healthy workers: A cohort study
    Yesung Lee, Woncheol Lee, Hyoung-Ryoul Kim
    Epidemiology and Health.2022; : e2022104.     CrossRef
Thyroid
Current Guidelines for Management of Medullary Thyroid Carcinoma
Mijin Kim, Bo Hyun Kim
Endocrinol Metab. 2021;36(3):514-524.   Published online June 22, 2021
DOI: https://doi.org/10.3803/EnM.2021.1082
  • 10,691 View
  • 1,000 Download
  • 15 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the parafollicular cells. The diagnostic and therapeutic strategies for the condition are different from those used for well-differentiated thyroid cancer. Since the 2015 American Thyroid Association guidelines for the diagnosis and treatment of MTC, the latest, including the National Comprehensive Cancer Network and European Association for Medical Oncology guidelines have been updated to reflect several recent advances in the management of MTC. Advances in molecular diagnosis and postoperative risk stratification systems have led to individualized treatment and follow-up strategies. Multi-kinase inhibitors, such as vandetanib and cabozantinib, can prolong disease progression-free survival with favorable adverse effects. In addition, potent selective rearranged during transfection (RET) inhibitors (selpercatinib and pralsetinib) have shown a promising efficacy in recent clinical trials. This review summarizes the management of MTC in recent guidelines focused on sporadic MTC.

Citations

Citations to this article as recorded by  
  • Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine
    Giorgio Treglia, Vittoria Rufini, Arnoldo Piccardo, Alessio Imperiale
    Seminars in Nuclear Medicine.2023;[Epub]     CrossRef
  • Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
    Linnea Højer Wang, Markus Wehland, Petra M. Wise, Manfred Infanger, Daniela Grimm, Michael C. Kreissl
    International Journal of Molecular Sciences.2023; 24(3): 2312.     CrossRef
  • A proposed grading scheme for predicting recurrence in medullary thyroid cancer based on the Ki67 index and metastatic lymph node ratio
    Pengfei Xu, Di Wu, Xuekui Liu
    Endocrine.2023; 81(1): 107.     CrossRef
  • Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literatur
    Marianna Hertelendi, Oulaya Belguenani, Azzeddine Cherfi, Ilya Folitar, Gabor Kollar, Berna Degirmenci Polack
    Biomedicines.2023; 11(4): 1024.     CrossRef
  • Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
    Faraat Ali, Kumari Neha, Garima Chauhan
    Archives of Pharmacal Research.2022; 45(5): 309.     CrossRef
  • Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC)
    Robin Lockridge, Sima Bedoya, Taryn Allen, Brigitte C. Widemann, Srivandana Akshintala, John Glod, Lori Wiener
    Children.2022; 9(6): 774.     CrossRef
  • Aggressive clinical course of medullary thyroid microcarcinoma
    Tamara Janić, Mirjana Stojković, Sanja Klet, Bojan Marković, Beleslin Nedeljković, Jasmina Ćirić, Miloš Žarković
    Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma.2022; 27(85): 63.     CrossRef
  • Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies
    Max Czajkowski, Daniel Kaemmerer, Jörg Sänger, Guido Sauter, Ralph M. Wirtz, Stefan Schulz, Amelie Lupp
    BMC Cancer.2022;[Epub]     CrossRef
  • Metastatic Risk Stratification of 2526 Medullary Thyroid Carcinoma Patients: A Study Based on Surveillance, Epidemiology, and End Results Database
    Minh-Khang Le, Masataka Kawai, Toru Odate, Huy Gia Vuong, Naoki Oishi, Tetsuo Kondo
    Endocrine Pathology.2022; 33(3): 348.     CrossRef
  • Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?
    Krzysztof Kaliszewski, Maksymilian Ludwig, Bartłomiej Ludwig, Agnieszka Mikuła, Maria Greniuk, Jerzy Rudnicki
    Cancers.2022; 14(15): 3643.     CrossRef
  • Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
    Giuseppe Fanciulli, Roberta Modica, Anna La Salvia, Federica Campolo, Tullio Florio, Nevena Mikovic, Alice Plebani, Valentina Di Vito, Annamaria Colao, Antongiulio Faggiano
    Cancers.2022; 14(16): 3991.     CrossRef
  • Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
    Davide Saronni, Germano Gaudenzi, Alessandra Dicitore, Silvia Carra, Maria Celeste Cantone, Maria Orietta Borghi, Andrea Barbieri, Luca Mignani, Leo J. Hofland, Luca Persani, Giovanni Vitale
    Cancers.2022; 14(18): 4442.     CrossRef
  • Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma
    Marine Sitbon, Porhuoy Chou, Seydou Bengaly, Brigitte Poirot, Marie Laloi-Michelin, Laure Deville, Atanas Pachev, Ahouefa Kowo-Bille, Clement Dumont, Cécile N Chougnet
    European Thyroid Journal.2022;[Epub]     CrossRef
  • Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation
    Juan Zhang, Dan Luo, Fang Li, Zhiyi Li, Xiaoli Gao, Jie Qiao, Lin Wu, Miaoling Li, Shao Liang
    Oxidative Medicine and Cellular Longevity.2021; 2021: 1.     CrossRef
  • THE ROLE OF CALCITONIN IN THE PREOPERATIVE STAGE AS THE PREDICTOR OF MEDULLARY THYROID CANCER METASTASES
    Volodymyr Palamarchuk , Viktor Smolyar , Oleksandr Tovkay, Oleksandr Nechay, Volodymyr Kuts , Revaz Sichinava , Oleh Mazur
    Ukrainian Scientific Medical Youth Journal.2021; 127(4): 68.     CrossRef
Bone Metabolism
Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach
Guido Zavatta, Bart L. Clarke
Endocrinol Metab. 2021;36(3):525-535.   Published online June 1, 2021
DOI: https://doi.org/10.3803/EnM.2021.1061
  • 3,512 View
  • 257 Download
  • 6 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Since normocalcemic primary hyperparathyroidism (NHPT) was first defined at the Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism in 2008, many papers have been published describing its prevalence and possible complications. Guidelines for the management of this condition are still lacking, and making the diagnosis requires fulfillment of strict criteria. Recent studies have shown that intermittent oscillations of serum calcium just below and slightly above the normal limits are very frequent, therefore challenging the assumption that serum calcium must be consistently normal to make the diagnosis. There is debate if these variations in serum calcium outside the normal range should be included under the rubric of NHPT or, rather, a milder form of classical primary hyperparathyroidism. Innovative approaches to define NHPT have been proposed that still need to be validated in prospective studies. Non-classical complications, especially cardiovascular complications, have been associated with NHPT, indicating that hyperparathyroidism may be a cardiovascular risk factor. New associations between parathyroid hormone (PTH) and several other comorbidities have also been reported from observational studies, suggesting that excessive PTH secretion might cause tissue dysfunction independent of serum calcium. Heterogeneous studies using different definitions of NHPT, however, make it difficult to draw definitive conclusions regarding the role of PTH excess when complications other than osteoporosis or kidney stones are described. This review will focus on clinical aspects and suggest an approach to NHPT.

Citations

Citations to this article as recorded by  
  • DXA-based bone strain index in normocalcemic primary hyperparathyroidism
    Gaia Tabacco, Anda Mihaela Naciu, Carmelo Messina, Gianfranco Sanson, Luca Rinaudo, Roberto Cesareo, Stefania Falcone, Nicola Napoli, Fabio Massimo Ulivieri, Andrea Palermo
    Osteoporosis International.2023; 34(5): 999.     CrossRef
  • Iperparatiroidismo primario normocalcemico
    Silvia Egiddi, Luigi Bonifazi Meffe, Anda Mihaela Naciu, Gaia Tabacco, Nicola Napoli, Andrea Palermo
    L'Endocrinologo.2023; 24(3): 249.     CrossRef
  • Evaluating Patients for Secondary Causes of Osteoporosis
    E. Michael Lewiecki
    Current Osteoporosis Reports.2022; 20(1): 1.     CrossRef
  • Preoperative Thoracic Muscle Mass Predicts Bone Density Change After Parathyroidectomy in Primary Hyperparathyroidism
    Seung Won Burm, Namki Hong, Seunghyun Lee, Gi Jeong Kim, Sang Hyun Hwang, Jongju Jeong, Yumie Rhee
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(6): e2474.     CrossRef
  • Applications of Metabolomics in Calcium Metabolism Disorders in Humans
    Beata Podgórska, Marta Wielogórska-Partyka, Joanna Godzień, Julia Siemińska, Michał Ciborowski, Małgorzata Szelachowska, Adam Krętowski, Katarzyna Siewko
    International Journal of Molecular Sciences.2022; 23(18): 10407.     CrossRef
  • Serum Calcium/Phosphorus Ratio in Biochemical Screening of Primary Hyperparathyroidism
    Nagihan Bestepe, Fatma Neslihan Cuhaci, Burcak Polat, Berna Evranos Ogmen, Didem Ozdemir, Reyhan Ersoy, Bekir Cakir
    Revista da Associação Médica Brasileira.2022; 68(12): 1668.     CrossRef
Bone Metabolism
Update on Glucocorticoid Induced Osteoporosis
Soo-Kyung Cho, Yoon-Kyoung Sung
Endocrinol Metab. 2021;36(3):536-543.   Published online June 1, 2021
DOI: https://doi.org/10.3803/EnM.2021.1021
  • 3,828 View
  • 273 Download
  • 7 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Glucocorticoids are used to treat many autoimmune and inflammatory diseases. However, an adverse systemic effect is a deleterious effect on bone, which may lead to glucocorticoid-induced osteoporosis, characterized by a rapid and transient increase in bone resorption and fracture risk, which may increase rapidly within 3 months of commencing oral glucocorticoids. Therefore, early risk assessment and intervention are crucial for preventing fractures in patients receiving glucocorticoids. Recent practice guidelines recommend an assessment for fracture risk in patients beginning or receiving glucocorticoids for more than 3 months, and they have suggested fracture risk assessment tool values for identifying patients who need preventive treatment. Bisphosphonates are currently the recommended first-line therapy for the prevention and treatment of glucocorticoid-induced osteoporosis. These have been shown to increase the bone mineral density in the spine and hip and to decrease the incidence of vertebral fractures. Recently, a more potent antiresorptive agent, denosumab, has been shown to increase the bone density in patients receiving glucocorticoids. Teriparatide has been shown to have a preventive effect on vertebral fractures, but not on nonvertebral fractures. In this article we aimed to provide an update on glucocorticoid-induced osteoporosis by focusing on the assessment of its risk and treatment options.

Citations

Citations to this article as recorded by  
  • Protective role of 3-oxypyridine derivatives in rats’ steroid-induced osteoporosis associated with reduced oxidative stress and recovery of nitric oxide formation
    A. P. Danilenko, K. S. Trunov, M. V. Pokrovsky, L. M. Danilenko, M. V. Korokin, O. S. Gudyrev, A. A. Khentov, N. P. Masalytina, I. A. Tatarenkova, A. V. Cherednichenko, E. V. Boeva, I. S. Koklin, E. I. Taran
    Pharmacy & Pharmacology.2023; 11(1): 48.     CrossRef
  • Vitamin D Supplementation in Patients with Juvenile Idiopathic Arthritis
    Chao-Yi Wu, Huang-Yu Yang, Shue-Fen Luo, Jing-Long Huang, Jenn-Haung Lai
    Nutrients.2022; 14(8): 1538.     CrossRef
  • A Review on the Molecular Mechanisms of Action of Natural Products in Preventing Bone Diseases
    Innocent U. Okagu, Timothy P. C. Ezeorba, Rita N. Aguchem, Ikenna C. Ohanenye, Emmanuel C. Aham, Sunday N. Okafor, Carlotta Bollati, Carmen Lammi
    International Journal of Molecular Sciences.2022; 23(15): 8468.     CrossRef
  • Antiosteoporosis and bone protective effect of nimbolide in steroid‐induced osteoporosis rats
    Jiang Huo, Yu Ding, Xinyuan Wei, Qi Chen, Bin Zhao
    Journal of Biochemical and Molecular Toxicology.2022;[Epub]     CrossRef
  • Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
    Lianghai Jiang, Jian Dong, Jianwei Wei, Lantao Liu
    BMC Musculoskeletal Disorders.2022;[Epub]     CrossRef
  • Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial
    Toshihiro Nanki, Mai Kawazoe, Kiyoko Uno, Wataru Hirose, Hiroaki Dobashi, Hiroshi Kataoka, Toshihide Mimura, Hiroshi Hagino, Hajime Kono
    Journal of Clinical Medicine.2022; 12(1): 292.     CrossRef
  • Understanding of Glucocorticoid Induced Osteoporosis
    Chang-Nam Son
    Keimyung Medical Journal.2021; 40(2): 69.     CrossRef
Bone Metabolism
Long-Term Treatment of Postmenopausal Osteoporosis
Jacques P. Brown
Endocrinol Metab. 2021;36(3):544-552.   Published online June 22, 2021
DOI: https://doi.org/10.3803/EnM.2021.301
  • 6,889 View
  • 470 Download
  • 13 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting. Case finding strategies have been developed and effective pharmacological interventions are available. This publication addresses how best to use the pharmacological options available for postmenopausal osteoporosis to provide lifelong fracture protection in patients at high and very high risk of fracture. The benefit of osteoporosis therapies far outweighs the rare risks.

Citations

Citations to this article as recorded by  
  • CircRNA hsa_circ_0006859 inhibits the osteogenic differentiation of BMSCs and aggravates osteoporosis by targeting miR-642b-5p/miR-483-3p and upregulating EFNA2/DOCK3
    Peng Yin, Yuan Xue
    International Immunopharmacology.2023; 116: 109844.     CrossRef
  • Resveratrol induces proliferation and differentiation of mouse pre-osteoblast MC3T3-E1 by promoting autophagy
    Weiye Cai, Bin Sun, Chao Song, Fei Liu, Zhengliang Wu, Zongchao Liu
    BMC Complementary Medicine and Therapies.2023;[Epub]     CrossRef
  • Oridonin Attenuates Thioacetamide-Induced Osteoclastogenesis Through MAPK/NF-κB Pathway and Thioacetamide-Inhibited Osteoblastogenesis Through BMP-2/RUNX2 Pathway
    XiaoLi Jin, Jia Xu, Fanfan Yang, Jin Chen, Feng Luo, Bin Xu, Jian Xu
    Calcified Tissue International.2023; 112(6): 704.     CrossRef
  • Phytochemical Compounds Involved in the Bone Regeneration Process and Their Innovative Administration: A Systematic Review
    Alina Hanga-Farcaș, Florina Miere (Groza), Gabriela Adriana Filip, Simona Clichici, Luminita Fritea, Laura Grațiela Vicaș, Eleonora Marian, Annamaria Pallag, Tunde Jurca, Sanda Monica Filip, Mariana Eugenia Muresan
    Plants.2023; 12(10): 2055.     CrossRef
  • Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates
    Yun Sun Lee, So Jeong Park, Jin Young Lee, Eunah Choi, Beom-Jun Kim
    The Korean Journal of Internal Medicine.2022; 37(4): 821.     CrossRef
  • ED-71 inhibited osteoclastogenesis by enhancing EphrinB2–EphB4 signaling between osteoclasts and osteoblasts in osteoporosis
    Yuan Zhang, Yuying Kou, Panpan Yang, Xing Rong, Rong Tang, Hongrui Liu, Minqi Li
    Cellular Signalling.2022; 96: 110376.     CrossRef
  • Effects of Muscles on Bone Metabolism—with a Focus on Myokines
    Beom-Jun Kim
    Annals of Geriatric Medicine and Research.2022; 26(2): 63.     CrossRef
  • Evaluation of the tolerability of zoledronic acid preparations for parenteral administration
    I. A. Shafieva, S. V. Bulgakova, A. V. Shafieva
    Meditsinskiy sovet = Medical Council.2022; (11): 96.     CrossRef
  • Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures
    Baohui Wang, Yindi Sun, Da Shi, Xiuwei Han, Na Liu, Bo Wang, Zhijun Liao
    BioMed Research International.2022; 2022: 1.     CrossRef
  • Current use of bone turnover markers in the management of osteoporosis
    Jacques P. Brown, Andrew Don-Wauchope, Pierre Douville, Caroline Albert, Samuel D. Vasikaran
    Clinical Biochemistry.2022; 109-110: 1.     CrossRef
  • Study on the influence of balloon dilation mode on the intravertebral cleft of osteoporotic fracture
    Nanning Lv, Xiaoxiao Feng, Haojun Liu, Xuejun Jia, Shanqin Han, Mingming Liu
    BMC Surgery.2022;[Epub]     CrossRef
  • An Acid-Sensitive Bone Targeting Delivery System Carrying Acacetin Prevents Osteoporosis in Ovariectomized Mice
    Xiaochen Sun, Chenyu Song, Chenxi Zhang, Chunlei Xing, Juan Lv, Huihui Bian, Nanning Lv, Dagui Chen, Xin Dong, Mingming Liu, Li Su
    Pharmaceuticals.2022; 16(1): 2.     CrossRef
  • Changes in Serum Dickkopf-1, RANK Ligand, Osteoprotegerin, and Bone Mineral Density after Allogeneic Hematopoietic Stem Cell Transplantation Treatment
    Eunhee Jang, Jeonghoon Ha, Ki-Hyun Baek, Moo Il Kang
    Endocrinology and Metabolism.2021; 36(6): 1211.     CrossRef
Adrenal Gland
Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation
Byung Kwan Park, Masashi Fujimori, Shu-Huei Shen, Uei Pua
Endocrinol Metab. 2021;36(3):553-563.   Published online June 1, 2021
DOI: https://doi.org/10.3803/EnM.2021.1008
  • 2,585 View
  • 111 Download
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Thermal ablation is a good alternative treatment in patients who are unable to undergo adrenalectomy. Even though the Asian Conference on Tumor Ablation (ACTA) has been held for many years, adrenal ablation guidelines have not been established. No guidelines for adrenal ablation are established in American and European countries, either. The aim of this review was to introduce the first version of ACTA guidelines for adrenal tumor ablation.
Miscellanenous
Cushing Syndrome Associated Myopathy: It Is Time for a Change
Martin Reincke
Endocrinol Metab. 2021;36(3):564-571.   Published online June 18, 2021
DOI: https://doi.org/10.3803/EnM.2021.1069
  • 3,392 View
  • 142 Download
  • 9 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Cushing syndrome is the result of excessive levels of glucocorticoids. Endogenous Cushing syndrome is rare with an incidence of two to three cases per million per year. Clinically, the presentation consists of a characteristic phenotype including skin symptoms and metabolic manifestations. A frequent co-morbidity with high impact on quality of life is Cushing syndrome associated myopathy. It characteristically affects the proximal myopathy, impairing stair climbing and straightening up. The pathophysiology is complex and involves protein degradation via the forkhead box O3 (FOXO3) pathway, intramuscular fat accumulation, and inactivity-associated muscle atrophy. Surgical remission of Cushing syndrome is the most important step for recovery of muscle function. Restoration depends on age, co-morbidities and postoperative insulin-like growth factor concentrations. At average, functionality remains impaired during the long-term compared to age and sex matched control persons. Growth hormone therapy in individuals with impaired growth hormone secretion could be an option but has not been proved in a randomized trial.

Citations

Citations to this article as recorded by  
  • The Link between Mitochondrial Dysfunction and Sarcopenia: An Update Focusing on the Role of Pyruvate Dehydrogenase Kinase 4
    Min-Ji Kim, Ibotombi Singh Sinam, Zerwa Siddique, Jae-Han Jeon, In-Kyu Lee
    Diabetes & Metabolism Journal.2023; 47(2): 153.     CrossRef
  • Intelligent Systems for Muscle Tracking: A Review on Sensor‐Algorithm Synergy
    Arjun Putcha, Tien Nguyen, Regina Smith, Rachel Choffin, Wubin Bai
    Advanced Intelligent Systems.2023; : 2200351.     CrossRef
  • Sarcopenia in youth
    Han Na Jung, Chang Hee Jung, You-Cheol Hwang
    Metabolism.2023; 144: 155557.     CrossRef
  • Morbidität und Mortalität beim Cushing-Syndrom
    Frederick Vogel, Leah Braun, Martin Reincke
    Der Internist.2022; 63(1): 34.     CrossRef
  • Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside
    Vittoria Favero, Arianna Cremaschi, Chiara Parazzoli, Alberto Falchetti, Agostino Gaudio, Luigi Gennari, Alfredo Scillitani, Fabio Vescini, Valentina Morelli, Carmen Aresta, Iacopo Chiodini
    International Journal of Molecular Sciences.2022; 23(2): 673.     CrossRef
  • Long‐term morbidity and mortality in patients with Cushing's syndrome
    Leah T. Braun, Frederick Vogel, Martin Reincke
    Journal of Neuroendocrinology.2022;[Epub]     CrossRef
  • Clinical presentation and etiology of Cushing's syndrome: Data from ERCUSYN
    Elena Valassi
    Journal of Neuroendocrinology.2022;[Epub]     CrossRef
  • Pyruvate dehydrogenase kinase 4 promotes ubiquitin–proteasome system‐dependent muscle atrophy
    Ibotombi Singh Sinam, Dipanjan Chanda, Themis Thoudam, Min‐Ji Kim, Byung‐Gyu Kim, Hyeon‐Ji Kang, Jung Yi Lee, Seung‐Hoon Baek, Shin‐Yoon Kim, Bum Jin Shim, Dongryeol Ryu, Jae‐Han Jeon, In‐Kyu Lee
    Journal of Cachexia, Sarcopenia and Muscle.2022; 13(6): 3122.     CrossRef
  • Consensus on diagnosis and management of Cushing's disease: a guideline update
    Maria Fleseriu, Richard Auchus, Irina Bancos, Anat Ben-Shlomo, Jerome Bertherat, Nienke R Biermasz, Cesar L Boguszewski, Marcello D Bronstein, Michael Buchfelder, John D Carmichael, Felipe F Casanueva, Frederic Castinetti, Philippe Chanson, James Findling
    The Lancet Diabetes & Endocrinology.2021; 9(12): 847.     CrossRef
Editorial
Diabetes, Obesity and Metabolism
Identification of Protein Z as a Potential Novel Biomarker for the Diagnosis of Prediabetes
Seung-Hoi Koo
Endocrinol Metab. 2021;36(3):572-573.   Published online June 28, 2021
DOI: https://doi.org/10.3803/EnM.2021.303
  • 2,138 View
  • 99 Download
PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Original Articles
Thyroid
A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol
Eun Kyung Lee, Yea Eun Kang, Young Joo Park, Bon Seok Koo, Ki-Wook Chung, Eu Jeong Ku, Ho-Ryun Won, Won Sang Yoo, Eonju Jeon, Se Hyun Paek, Yong Sang Lee, Dong Mee Lim, Yong Joon Suh, Ha Kyoung Park, Hyo-Jeong Kim, Bo Hyun Kim, Mijin Kim, Sun Wook Kim, Ka Hee Yi, Sue K. Park, Eun-Jae Jung, June Young Choi, Ja Seong Bae, Joon Hwa Hong, Kee-Hyun Nam, Young Ki Lee, Hyeong Won Yu, Sujeong Go, Young Mi Kang, MASTER study group
Endocrinol Metab. 2021;36(3):574-581.   Published online May 26, 2021
DOI: https://doi.org/10.3803/EnM.2020.943
  • 4,309 View
  • 198 Download
  • 6 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
Postoperative thyroid stimulating hormone (TSH) suppression therapy is recommended for patients with intermediate- and high-risk differentiated thyroid cancer to prevent the recurrence of thyroid cancer. With the recent increase in small thyroid cancer cases, the extent of resection during surgery has generally decreased. Therefore, questions have been raised about the efficacy and long-term side effects of TSH suppression therapy in patients who have undergone a lobectomy.
Methods
This is a multicenter, prospective, randomized, controlled clinical trial in which 2,986 patients with papillary thyroid cancer are randomized into a high-TSH group (intervention) and a low-TSH group (control) after having undergone a lobectomy. The principle of treatment includes a TSH-lowering regimen aimed at TSH levels between 0.3 and 1.99 μIU/mL in the low-TSH group. The high-TSH group targets TSH levels between 2.0 and 7.99 μIU/mL. The dose of levothyroxine will be adjusted at each visit to maintain the target TSH level. The primary outcome is recurrence-free survival, as assessed by neck ultrasound every 6 to 12 months. Secondary endpoints include disease-free survival, overall survival, success rate in reaching the TSH target range, the proportion of patients with major cardiovascular diseases or bone metabolic disease, the quality of life, and medical costs. The follow-up period is 5 years.
Conclusion
The results of this trial will contribute to establishing the optimal indication for TSH suppression therapy in low-risk papillary thyroid cancer patients by evaluating the benefit and harm of lowering TSH levels in terms of recurrence, metabolic complications, costs, and quality of life.

Citations

Citations to this article as recorded by  
  • ASO Author Reflections: Active Surveillance may be Possible in Patients with T1b Papillary Thyroid Carcinoma Over 55 Years of Age Without High-Risk Features on Preoperative Examinations
    Ho-Ryun Won, Eonju Jeon, Da Beom Heo, Jae Won Chang, Minho Shong, Je Ryong Kim, Hyemi Ko, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Kyong Hye Joung, Ji Min Kim, Younju Lee, Sung-Woo Kim, Young Ju Jeong, Yong Bae Ji, Kyung Tae, Bon Seok Koo
    Annals of Surgical Oncology.2023; 30(4): 2254.     CrossRef
  • Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer
    Arash Abiri, Khodayar Goshtasbi, Sina J. Torabi, Edward C. Kuan, William B. Armstrong, Tjoson Tjoa, Yarah M. Haidar
    Otolaryngology–Head and Neck Surgery.2023; 168(4): 745.     CrossRef
  • Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis
    Timothy M Ullmann, Maria Papaleontiou, Julie Ann Sosa
    The Journal of Clinical Endocrinology & Metabolism.2023; 108(2): 271.     CrossRef
  • Age-Dependent Clinicopathological Characteristics of Patients with T1b Papillary Thyroid Carcinoma: Implications for the Possibility of Active Surveillance
    Ho-Ryun Won, Eonju Jeon, Da Beom Heo, Jae Won Chang, Minho Shong, Je Ryong Kim, Hyemi Ko, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Kyong Hye Joung, Ji Min Kim, Younju Lee, Sung-Woo Kim, Young Ju Jeong, Yong Bae Ji, Kyung Tae, Bon Seok Koo
    Annals of Surgical Oncology.2023; 30(4): 2246.     CrossRef
  • Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma
    Mi Rye Bae, Sung Hoon Nam, Jong-Lyel Roh, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim
    Endocrine.2022; 75(2): 487.     CrossRef
  • The Concept of Economic Evaluation and Its Application in Thyroid Cancer Research
    Kyungsik Kim, Mijin Kim, Woojin Lim, Bo Hyun Kim, Sue K. Park
    Endocrinology and Metabolism.2021; 36(4): 725.     CrossRef
Thyroid
Insights from a Prospective Follow-up of Thyroid Function and Autoimmunity among COVID-19 Survivors
David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Carol Ho Yi Fong, Chun Yiu Law, Eunice Ka Hong Leung, Kelvin Kai Wang To, Kathryn Choon Beng Tan, Yu Cho Woo, Ching Wan Lam, Ivan Fan Ngai Hung, Karen Siu Ling Lam
Endocrinol Metab. 2021;36(3):582-589.   Published online June 8, 2021
DOI: https://doi.org/10.3803/EnM.2021.983
  • 8,016 View
  • 229 Download
  • 29 Citations
AbstractAbstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
The occurrence of Graves’ disease and Hashimoto thyroiditis after coronavirus disease 2019 (COVID-19) raised concerns that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may trigger thyroid autoimmunity. We aimed to address the current uncertainties regarding incident thyroid dysfunction and autoimmunity among COVID-19 survivors.
Methods
We included consecutive adult COVID-19 patients without known thyroid disorders, who were admitted to Queen Mary Hospital from July 21 to September 21, 2020 and had serum levels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine (fT3), and anti-thyroid antibodies measured both on admission and at 3 months.
Results
In total, 122 patients were included. Among 20 patients with abnormal thyroid function tests (TFTs) on admission (mostly low fT3), 15 recovered. Among 102 patients with initial normal TFTs, two had new-onset abnormalities that could represent different phases of thyroiditis. Among 104 patients whose anti-thyroid antibody titers were reassessed, we observed increases in anti-thyroid peroxidase (TPO) (P<0.001) and anti-thyroglobulin (P<0.001), but not anti-thyroid stimulating hormone receptor titers (P=0.486). Of 82 patients with negative anti-TPO findings at baseline, 16 had a significant interval increase in anti-TPO titer by >12 U, and four became anti-TPO-positive. Worse baseline clinical severity (P=0.018), elevated C-reactive protein during hospitalization (P=0.033), and higher baseline anti-TPO titer (P=0.005) were associated with a significant increase in anti-TPO titer.
Conclusion
Most patients with thyroid dysfunction on admission recovered during convalescence. Abnormal TFTs suggestive of thyroiditis occurred during convalescence, but infrequently. Importantly, our novel observation of an increase in anti-thyroid antibody titers post-COVID-19 warrants further follow-up for incident thyroid dysfunction among COVID-19 survivors.

Citations

Citations to this article as recorded by  
  • The most common persistent symptoms in patients with COVID-19 who were evaluated in the Internal Medicine polyclinic
    Zeynep KOÇ, Seydahmet AKIN
    The European Research Journal.2023; 9(1): 97.     CrossRef
  • Clinical assessment of children with long COVID syndrome
    Réka Garai, Péter Krivácsy, Vivien Herczeg, Fanni Kovács, Bálint Tél, Judit Kelemen, Anna Máthé, Eszter Zsáry, Johanna Takács, Dániel Sándor Veres, Attila J. Szabó
    Pediatric Research.2023; 93(6): 1616.     CrossRef
  • T Cell Receptor Sequences Amplified during Severe COVID-19 and Multisystem Inflammatory Syndrome in Children Mimic SARS-CoV-2, Its Bacterial Co-Infections and Host Autoantigens
    Robert Root-Bernstein, Elizabeth Churchill, Shelby Oliverio
    International Journal of Molecular Sciences.2023; 24(2): 1335.     CrossRef
  • A Literature Review on SARS-CoV-2 and Other Viruses in Thyroid Disorders: Environmental Triggers or No-Guilty Bystanders?
    Francesca Gorini, Cristina Vassalle
    International Journal of Environmental Research and Public Health.2023; 20(3): 2389.     CrossRef
  • Thyroid dysfunction as a long-term post-COVID-19 complication in mild-to-moderate COVID-19
    Vesselina Yanachkova, Teodora Stankova, Radiana Staynova
    Biotechnology & Biotechnological Equipment.2023; 37(1): 194.     CrossRef
  • The Influence of SARS-CoV-2 Infection on the Thyroid Gland
    Aleksandra Piekarska, Marta Góral, Marta Kozula, Aleksandra Jawiarczyk-Przybyłowska, Katarzyna Zawadzka, Marek Bolanowski
    Biomedicines.2023; 11(2): 614.     CrossRef
  • Thyroid Function Abnormalities and Outcomes in Hospitalized Patients with COVID-19 Infection: A Cross-Sectional Study
    Deepika Patel, Dukhabandhu Naik, Sadishkumar Kamalanathan, Kadhiravan Tamilarasu, Jayaprakash Sahoo, Ayan Roy, Chandhana Merugu, Varun Suryadevara
    Hormone and Metabolic Research.2023; 55(03): 169.     CrossRef
  • The Spectrum of Thyroid Function Tests and Autoantibodies During Hospitalization and After Six Months of Discharge in COVID-19 Patients: Does COVID-19 Trigger Autoimmunity?
    Ziynet Alphan Uc, Pinar Yagcı, Zelal Adibelli, Cevdet Duran
    Endocrine Research.2023; : 1.     CrossRef
  • Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
    Alessandro Rossini, Sara Cassibba, Francesca Perticone, Simone Vasilij Benatti, Serena Venturelli, Greta Carioli, Arianna Ghirardi, Marco Rizzi, Tiziano Barbui, Roberto Trevisan, Silvia Ippolito
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • A prospective follow-up of thyroid volume and thyroiditis features on ultrasonography among survivors of predominantly mild to moderate COVID-19
    Man Him Matrix Fung, David Tak Wai Lui, Keith Wan Hang Chiu, Sherman Haynam Lee, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Connie Hong Nin Loong, Chun Yiu Law, Kelvin Kai Wang To, Ching W
    PeerJ.2023; 11: e15034.     CrossRef
  • Study on Clinicopathological Features and Risk Factors of Patients with Multiple Primary Breast Cancers and Thyroid Disease
    Jie Li, Yonghong Liu, Jian Jin, Qingfeng Shi, Yanting Ji, Bo Zhang, Pengfei Hu, Jinghua Pan
    Mediators of Inflammation.2023; 2023: 1.     CrossRef
  • Autoimmune complications of COVID‐19
    Niloufar Yazdanpanah, Nima Rezaei
    Journal of Medical Virology.2022; 94(1): 54.     CrossRef
  • The Independent Association of TSH and Free Triiodothyronine Levels With Lymphocyte Counts Among COVID-19 Patients
    David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Chloe Yu Yan Cheung, Carol Ho Yi Fong, Chun Yiu Law, Kelvin Kai Wang To, Ching Wan Lam, Kathryn Choon Beng Tan, Yu Cho Woo, Ivan Fan Ngai Hung,
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Comment on Khunti et al. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care 2021;44:2645–2655
    Carmine Gazzaruso, Adriana Coppola, Pietro Gallotti, Ileana Terruzzi, Tiziana Montalcini, Livio Luzi
    Diabetes Care.2022; 45(2): e45.     CrossRef
  • The potential impact of COVID-19 on thyroid gland volumes among COVID-19 survivors
    Emre Urhan, Zuleyha Karaca, Canan Sehit Kara, Zeynep Ture Yuce, Kursad Unluhizarci
    Endocrine.2022; 76(3): 635.     CrossRef
  • Systematic review of COVID-19 and autoimmune thyroiditis
    Esra Tutal, Resat Ozaras, Hakan Leblebicioglu
    Travel Medicine and Infectious Disease.2022; 47: 102314.     CrossRef
  • The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
    Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea
    Diagnostics.2022; 12(4): 960.     CrossRef
  • Should we expect a wave of type 1 diabetes following SARS‐CoV‐2 pandemic?
    Laura Montefusco, Andrea Mario Bolla, Paolo Fiorina
    Diabetes/Metabolism Research and Reviews.2022;[Epub]     CrossRef
  • COVID-19 and Thyroid Function: A Bi-Directional Two-Sample Mendelian Randomization Study
    Gloria Hoi-Yee Li, Ching-Man Tang, Ching-Lung Cheung
    Thyroid.2022; 32(9): 1037.     CrossRef
  • Development of a prediction score (ThyroCOVID) for identifying abnormal thyroid function in COVID-19 patients
    D. T. W. Lui, C. H. Lee, W. S. Chow, A. C. H. Lee, A. R. Tam, C. Y. Y. Cheung, C. H. Y. Fong, S. T. M. Kwok, C. Y. Law, K. K. W. To, C. W. Lam, K. C. B. Tan, Y. C. Woo, I. F. N. Hung, K. S. L. Lam
    Journal of Endocrinological Investigation.2022; 45(11): 2149.     CrossRef
  • Symptomatic Bradycardia Manifesting as Acute Hypothyroidism Following COVID-19 Infection: A Case Report
    Jaydip Desai, Arsh N Patel, Courtney L Evans, Molly Triggs, Fulton Defour
    Cureus.2022;[Epub]     CrossRef
  • Schilddrüse und SARS-CoV-2
    Georg Zettinig
    Journal für Klinische Endokrinologie und Stoffwechsel.2022; 15(3): 100.     CrossRef
  • Thyroid diseases are associated with coronavirus disease 2019 infection
    Yutian Tian, Junyu Zhao, Tingting Wang, Haipeng Wang, Jinming Yao, Song Wang, Yaru Mou
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Thyrotropin Levels in Patients with Coronavirus Disease 2019: Assessment during Hospitalization and in the Medium Term after Discharge
    Abdallah Al-Salameh, Noémie Scherman, Imane Adda, Juliette André, Yoann Zerbib, Julien Maizel, Jean-Daniel Lalau, Etienne Brochot, Claire Andrejak, Rachel Desailloud
    Life.2022; 12(12): 2014.     CrossRef
  • Long COVID in Patients With Mild to Moderate Disease: Do Thyroid Function and Autoimmunity Play a Role?
    David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Chun Yiu Law, Eunice Ka Hong Leung, Kelvin Kai Wang To, Kathryn Choon Beng Tan, Yu Cho Woo, Ching Wan Lam, Ivan Fan Ngai Hung,
    Endocrine Practice.2021; 27(9): 894.     CrossRef
  • Hashimoto’s thyroiditis following SARS-CoV-2 infection
    Rafael Silvestre Knack, Taliê Hanada, Renata Silvestre Knack, Kamilla Mayr
    BMJ Case Reports.2021; 14(8): e244909.     CrossRef
  • Higher SARS-CoV-2 viral loads correlated with smaller thyroid volumes on ultrasound among male COVID-19 survivors
    David Tak Wai Lui, Matrix Man Him Fung, Keith Wan Hang Chiu, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Connie Hong Nin Loong, Wade Wei Wong, Cassandra Yuen Yan Lee, Chun Yiu Law, Kelvin K
    Endocrine.2021; 74(2): 205.     CrossRef
  • SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases
    Avaniyapuram Kannan Murugan, Ali S Alzahrani
    Journal of Inflammation Research.2021; Volume 14: 6191.     CrossRef
  • POST-COVID ENDOCRINOPATHY :ABOUT A CASE ENDOCRINOPATHIE POST- COVID :À PROPOS D’UN CAS
    S. Rafi, G. Elmghari, N, Elansari
    INDIAN JOURNAL OF APPLIED RESEARCH.2021; : 13.     CrossRef
Thyroid
Effect of Cigarette Smoking on Thyroid Cancer: Meta-Analysis
Joon-Hyop Lee, Young Jun Chai, Ka Hee Yi
Endocrinol Metab. 2021;36(3):590-598.   Published online May 26, 2021
DOI: https://doi.org/10.3803/EnM.2021.954
  • 3,331 View
  • 151 Download
  • 2 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
Although smoking is generally carcinogenic, its effect on thyroid cancers is still subject to controversy. The purpose of this study was to summarize the role of smoking in relation to thyroid cancer occurrence.
Methods
We performed a meta-analysis of 24 eligible studies: 21 case-control studies and three prospective cohort studies. The summary odds ratio (OR) and 95% confidence interval (CI) of all studies were acquired based on random effect model. Further subgroup analyses were conducted according to gender, histological type of thyroid cancer, and smoking status of patients for the case-control studies.
Results
The summary effect size indicated a negative association of smoking for thyroid cancer (OR, 0.798; 95% CI, 0.681 to 0.935). From the subgroup analyses for the case-control studies, reduced risk of thyroid cancer was observed in both men (OR, 0.734; 95% CI, 0.553 to 0.974) and women (OR, 0.792; 95% CI, 0.700 to 0.897). The protective effect of smoking was observed in studies in which thyroid cancer was limited to differentiated thyroid cancers (DTCs) (OR, 0.798; 95% CI, 0.706 to 0.902).
Conclusion
Our results suggests that smoking may have a protective effect on thyroid cancer, especially on DTCs. Further studies with larger sample sizes should be conducted in elucidating the dose and time dependent effect of smoking on thyroid cancer with specific focus on the types of thyroid cancers.

Citations

Citations to this article as recorded by  
  • Relationship between Serum Levels of Selenium and Thyroid Cancer: A Systematic Review and Meta-Analysis
    Runhua Hao, Ping Yu, Lanlan Gui, Niannian Wang, Da Pan, Shaokang Wang
    Nutrition and Cancer.2023; 75(1): 14.     CrossRef
  • Longitudinal Changes in Smoking Habits in Women and Subsequent Risk of Cancer
    Thi Xuan Mai Tran, Soyeoun Kim, Huiyeon Song, Boyoung Park
    American Journal of Preventive Medicine.2022; 63(6): 894.     CrossRef
Thyroid
Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves’ Disease and Hashimoto’s Thyroiditis in Korean Patients
Jee Hee Yoon, Min-ho Shin, Hee Nam Kim, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
Endocrinol Metab. 2021;36(3):599-606.   Published online June 2, 2021
DOI: https://doi.org/10.3803/EnM.2021.965
  • 2,966 View
  • 96 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
Programmed cell death-ligand 1 (PD-L1) has an important role in regulating immune reactions by binding to programmed death 1 (PD-1) on immune cells, which could prevent the exacerbation of autoimmune thyroid disease (AITD). The aim of this study was to evaluate the association of PD-L1 polymorphism with AITD, including Graves’ disease (GD) and Hashimoto’s thyroiditis (HT).
Methods
A total of 189 GD patients, 234 HT patients, and 846 healthy age- and sex-matched controls were enrolled in this study. We analyzed PD-L1 single nucleotide polymorphism (SNP) (rs822339) and investigated the associations with clinical disease course and outcome.
Results
Genotype frequency at the PD-L1 marker RS822339 in GD (P=0.219) and HT (P=0.764) patients did not differ from that among healthy controls. In patients with GD, the A/G or G/G genotype group demonstrated higher TBII titer (20.6±20.5 vs. 28.0± 25.8, P=0.044) and longer treatment duration (39.0±40.4 months vs. 62.4±65.0 months, P=0.003) compared to the A/A genotype group. Among patients in whom anti-thyroid peroxidase (TPO) antibody was measured after treatment of GD, post-treatment antiTPO positivity was higher in the A/G or G/G genotype group compared to the A/A genotype group (48.1% vs. 69.9%, P=0.045). Among patients with HT, there was no significant difference of anti-TPO antibody positivity (79.4% vs. 68.6%, P=0.121), anti-thyroglobulin antibody positivity (80.9% vs. 84.7%, P=0.661), or development to overt hypothyroidism (68.0% vs. 71.1%, P=0.632) between the A/A genotype group and the A/G or G/G genotype group.
Conclusion
The genotype frequency of PD-L1 (rs822339) is not different in patients with AITD compared with healthy controls. The intact PD-1/PD-L1 pathway in GD and HT might be important to maintain chronicity of AITD by protecting immune tolerance. However, the PD-L1 SNP could be associated with difficulty in achieving remission in patients with GD, which may be helpful to predict the possibility of longer treatment. Further studies are required to investigate the complex immune tolerance system in patients with AITD.

Endocrinol Metab : Endocrinology and Metabolism